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What are the new approaches and emerging ideas to prevent leptospirosis, a neglected bacterial re-
emerging zoonotic disease? How do Leptospira interrogans escape the host defenses? We aim here to
review and discuss the most recent literature that provides some answers to these questions, in
particular data related to a better understanding of adaptive and innate immunity towards leptospires,
and design of vaccines. This is an opinion paper, not a comprehensive review. We will try to highlight the
new strategies and technologies boosting the search for drugs and vaccines. We will also address the
bottlenecks and difﬁculties impairing the search for efﬁcient vaccines and the many gaps in our
knowledge of immunity against leptospirosis. Finally, we aim to delineate how Leptospira spp. escape the
innate immune responses of Toll-Like receptors (TLR) and Nod-Like receptors (NLR). The rational use of
TLR and NLR agonists as adjuvants could be key to design future vaccines against pathogenic leptospires.
© 2018 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.1. Introduction: state of the art
Identiﬁed more than 100 years ago, Leptospira interrogans are
spirochetes responsible for leptospirosis, also known in its severe
form as Weil's disease. For years, leptospirosis has been considered
as a dimorphic zoonosis. It was presented in humans, and other
incidental hosts, as an acute disease with blood dissemination of
the bacteria provoking a potentially fatal, severe disease with
multi-organ failure, whereas it was described as an asymptomatic
renal colonization in chronic carriers, such as rats. However, recent
data suggest that mice, considered as “resistant”, may die from an
acute disease with uncontrolled leptospires proliferation in blood
after intraperitoneal injectionwith a high inoculum of L. interrogans
[1]; conversely, hamsters, used as a model of the acute disease, are
chronic carriers of leptospires when they survive experimental
infection [2]. Moreover, it has recently been shown that asymp-
tomatic renal carriage of leptospires in humans [3] and pet animals
such as dogs [4] has largely been underestimated. Therefore,
leptospirosis should be considered as a biphasic disease, starting
with an acute phase that is self-resolving in most of the cases, and
potentially followed by chronic kidney colonization, depending on
the virulence of the strain, the severity of the acute phase and thevier Masson SAS. All rights reserveimmune defense of the host. In both acute and chronic manifes-
tations, pathogenic leptospires demonstrate their peculiar ability to
overcome the immune system.
Antibiotics efﬁciently combat leptospirosis, provided they are
used early, before leptospires settle in the kidney [1]. The reference
treatments are penicillin during the acute phase and streptomycin
to cure kidney colonization [5]. However these antibiotic treat-
ments are not generalizable in the long run for animal or human
populations living in endemic areas.
In certain situations, prophylactic antibiotic treatments may be
appropriate. A treatment with one single dose of 200 mg of dox-
ycyclin can be used to prevent infection with L. interrogans in ath-
letes, soldiers and occasional travelers. Azithromycin also seems to be
efﬁcient according to our results in mice [1] and in humans (Vinetz,
personal communication). Treatments should be carefully evaluated
in each animal because the same molecule can present different
bioavailability, i.e. prophylaxis with doxycyclin is not efﬁcient inmice
because of its reduced life-span compared to humans [1].
Antimicrobial peptides are important components of the
eukaryotic innate immune system and promising molecules that
have recently been envisioned to counteract leptospires. These
small cationic peptides are expressed by virtually all cells, upon
activation of pattern recognition receptors (PRR) by microbe asso-
ciated molecular patterns (MAMP). Besides their potent bacteri-
cidal role due tomembrane destabilization/depolarization and pored.
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defenses. It has been shown that the rapid expression of antimi-
crobial defensins participates in promoting acquired immune re-
sponses against a potential pathogen [6]. Hopefully, their use could
both destroy the leptospires and boost the adaptive immune
response (see 3.1 antimicrobial peptides).
Inactivated bacterins (suspensions of killed whole bacteria)
remain the only vaccines licensed at the present time. They
generate protective antibodies, but are restricted to a given serovar.
More than 200 serovars are deﬁned according to the highly
immunogenic O-antigen part of the leptospiral lipopolysaccharide
(LPS), a T-independent antigen known to generate short-term im-
munity [7]. Because of these limitations, there is no available uni-
versal vaccine that provides cross-protection between different
serovars and that is able to block renal colonization. In humans,
effective protection often requires repeated immunizations of
multivalent vaccines targeting different circulating serovars. This
strategy has been efﬁcient to reduce the incidence of human
leptospirosis in China and Cuba [8]. This also applies in veterinary
use to limit/avoid leptospiral dissemination in livestock.
Side effects due to the local injection of high numbers of bacteria
that may trigger adverse inﬂammatory and allergic reactions are
another limitation of such vaccines. Additionally, in some animals,
natural infection or vaccination might not systematically trigger a
humoral response. For example, in Brazil, multivalent commercial
vaccines have been shown inefﬁcient to protect cattle, associated
with a complete lack of antibody response [9]. Microscopic agglu-
tination test (MAT) is the gold standard method to determine the
serovar speciﬁcity and antibody titers in the serum of infected
hosts, using a panel of live leptospires representing the prevalent
serovars. A recent study highlighted the fact that in a herd of bo-
vines, from which leptospires have been isolated in urine, most of
the individuals was tested negative by MAT of their own serovars,
including after addition of the local serovar in the MAT panel [10].
These data raise the important issue that individuals with renal
colonization and urine excretion of L. interrogans may not be
detected by MAT, and that other more sensitive tests such as PCR
detection of leptospiral DNA should be used. Besides demonstra-
tions that MAT is not sufﬁciently sensitive and difﬁcult to interpret,
these observations also suggests that 1) once in their renal niche,
leptospires may avoid to trigger the humoral immune response,
and 2) in vivo modiﬁcation of surface proteins of infecting lepto-
spires may be responsible for the inefﬁciency of the elicited anti-
bodies to recognize in vitro cultured serovars/strains (see 2.2 Post-
translational modiﬁcations).
Interestingly, in 2010, studies from the Adler/Murray's group
suggested that live attenuated strains with mutation in the LPS
biosynthetic pathway [11] protect and induce cross-protection in
the hamster model [12]. Although live leptospires, even attenuated,
may not be the best option for human vaccines, this study is of great
interest since it suggests that the LPS masks the protein antigens
and demonstrates that targeting conserved exposed protein anti-
gens is a relevant strategy to get protective and cross reactive
vaccines.
Recombinant subunit vaccines are safer than bacterins or live
attenuated strains and are largely used to ﬁght infectious diseases.
Several recombinant vaccines trials suggest that leptospiral lipo-
proteins aremore or less efﬁcient to protect against lethal challenge
but usually do not succeed in sterilizing kidneys [7]. The example of
the LipL32 lipoprotein should serve as a caution. This lipoprotein is
a very well conserved antigen but proves not to be protective,
potentially due to its subcellular localization. Milestones, such as
speciﬁc antibodies and doing basic tests such as proteinase K
“shaving” or immunoﬂuorescence, are essential to insure that the
candidate has some chance to be recognized by the host immuneantibodies before moving on to animal experiments. However,
several lipoproteins that are surface exposed have also proven not
to be good vaccines as recombinant proteins. The only convincing
example of an efﬁcient subunit vaccine is a recent study using the
adhesion protein LigB [13], although a concurrent study challenged
the rationale of this success (see 3.3 Subunit vaccines). Hopefully,
the availability of large genomic data banks and elaborated struc-
ture prediction algorithms, which have recently revolutionized
vaccine design, will help our ﬁeld to develop efﬁcient subunit
vaccines against leptospirosis (see 3.2 Reverse and structural
vaccinology).
Adjuvants, designed to enhance duration, broadness, and
magnitude of antibody production, improve the adaptive immune
response to a vaccine antigen. They usually have a dual action: they
mechanically favor a slow local delivery of the vaccine and they
activate PRR. Hence, they trigger pro-inﬂammatory pathways, fa-
voring immune cell inﬁltration, capture, degradation and they
promote antigen presentation by dendritic cells (DCs), allowing
effector cell maturation. They also reduce the amount of antigen
required for immunization, limiting potential local side effects. In
contrast to many bacterial infections, leptospirosis and bacterins
mostly elicit a T-independent, short-lasting immune response. It
indicates that Leptospira spp. by themselves, even alive, are not self-
adjuvanting. It is therefore of interest to study how Leptospira spp.
escape the innate immune response (See 2.1 Complement escape
and 2.3 TLR and NLR species-speciﬁc recognition and escape of
leptospires) in order to understand how they escape phagocytosis.
The ﬁnal goal of these studies would be to use tailored adjuvants to
design leptospiral vaccines (see 3.4 Adjuvants), capable at eliciting
a memory response.
Depending on their immune defenses, animals may develop a
large spectrum of leptospiral clinical symptoms; from asymptom-
atic to mild or severe disease, potentially leading to renal coloni-
zation, or even to a lethal outcome. Effective anti-leptospiral
treatments should target a large panel of hosts. However, different
hosts may present species-speciﬁcity of recognition of leptospiral
MAMPs [14,15] (see 2.3 TLR and NLR species-speciﬁc recognition
and escape of leptospires). Therefore it is very important to study
several animal models and strains to comprehend the immune
reactions [16].
Arguably, several recent studies emphasized the role of ani-
mals (wild or peridomestic) as reservoirs of leptospires [4,17,18].
In particular, the urine is recognized as a favorite route for host
shedding of leptospires. As demonstrated in Europe with a wide
variety of animals, one study in Tanzania reported that almost 30%
of wild animals were seroreactive against different Leptospira
species and serogroups [19], while another study reported renal
carriage among 31% of the mammals tested [20]. Although rats are
considered to be the carrier that excretes the highest quantity of
leptospires per milliliter of urine, transmission to humans via
large mammals, such as cattle, may be more important because of
the volume of urine excreted. Correlation between biomes and
species/serogroups has been studied in Latin America and West-
ern Indian Ocean islands in order to better understand how the
infection is spread. For example in the Seychelles, a recent study
showed that rats which are identiﬁed as targets for eradication,
are not the main reservoir of Leptospira spp. infecting humans.
Also, dogs (but not bats) in La Reunion, and ternecs (a small
mammal) in Mayotte, have been shown to be reservoir of patho-
genic Leptospira spp. contaminating humans [18,17]. Because it
seems obvious that serogroups of leptospires are frequently
associated with speciﬁc animal species, it is very important to
target and customize ways to ﬁght the spread of infection
depending on the context (epidemiological, geographical, socio-
economic).
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2.1. Complement/phagocytosis escape
The most important feature explaining the success of patho-
genic leptospires to virtually infect all vertebrates (from ﬁshes to
mammals) is their ability to escape the complement system, which
is the most immediate and efﬁcient innate defense. Pathogenic
leptospires use different sophisticated strategies to subvert or
inactivate all 3 pathways (classical, alternative and lectins) of the
complement cascade. Such mechanisms include covering them-
selves with host proteases or regulatory complement proteins and
secreting proteases. This is not the case of the saprophytic strains
that are sensitive to the complement system, and therefore not
pathogenic (see the recent review from Barbosa [21]).
Linked to complement evasion, pathogenic leptospires largely
escape phagocytosis unless opsonized by speciﬁc antibodies [22].
Neutrophils are barely efﬁcient to counteract pathogenic lepto-
spires, but it has been shown ex vivo that L. interrogans are killed
by Neutrophil Extracellular Traps (NET) [23]. Neutrophilia is
observed in human patients with leptospirosis, but neutrophils
are surprisingly not activated [24]. By opposition, in mice, lepto-
spires do not trigger the recruitment of neutrophils in kidneys
[25,15], although they recruit macrophages. Interestingly, a recent
study showed that in murine macrophages, most of the killing of
leptospires occurred through Reactive Oxygen Species (ROS),
whereas L. interrogans barely stimulated ROS production in the
THP-1 human macrophage cell line [26]. This is in line with a
previous study from the same group showing cytosolic survival of
leptospires in human macrophages, although murine macro-
phages would kill leptospires, present in vesicles [27]. Ongoing
projects in our group aim to understand the underlying host-
pathogen mechanisms responsible for the differential human
and murine recruitment of macrophages and neutrophils, and
their respective killing abilities. This could be instrumental to
design strategies that restore the host killing ability against
pathogenic Leptospira spp.
2.2. Post-translational modiﬁcations
An important study came from the group of Nally, using the
virulent strain RJ16441 of L. interrogans serovar Copenhageni,
isolated from the blood of a patient with a severe pulmonary form
of leptospirosis. This strain can trigger a lethal infection in the
guinea pig model or an asymptomatic infection with renal colo-
nization in the rat model. It was shown that leptospires recovered
from livers of moribund guinea pigs presented a modiﬁed LPS,
with a shortened O-antigen part compared to bacteria cultured in
EMJH at 30 C, or recovered from kidneys of infected asymp-
tomatic rats [28]. In the same line, post-translational modiﬁca-
tions (PTM) on LipL32 have been shown to occur in leptospires
retrieved from the urine of rats infected with L. interrogans serovar
Copenhageni. In these bacteria, LipL32 was acetylated or tri-
methylated on lysines, including those shown to be part of epi-
topes recognized by antibodies [29]. Therefore, PTM of LPS and
LipL32 most probably constitute a leptospiral strategy to escape
the immune response. Very interesting studies from the groups of
Nally and Caimano addressed more generally the question of
in vivo modiﬁcations of leptospiral proteins. Dyalysis membrane
chambers (DMC) were inoculated with L. interrogans then
implanted for 10 days in the rat peritoneal cavity before bacterial
recovery. Compared to EMJH cultured bacteria, the authors
showed by RNA-Seq that leptospires retrieved from DMC modu-
lated the expression of 166 genes at the mRNA level. Then
following mass spectrometry analysis of proteins separated by 2-D gel electrophoresis, they showed that LoA22, an outer lipopro-
tein important for virulence, LipL32, LipL41 and chaperone pro-
teins, are more abundant in vivo. In addition, these proteins were
identiﬁed to have post-translational modiﬁcations, such as
phosphorylation or tri-methylations, not observed in vitro when
leptospires were grown in EMJH culture medium at 30 C or 37 C
[30]. Therefore, PTM of leptospiral proteins may constitute a
hurdle to generate effective vaccines from in vitro cultured bac-
teria, since candidate proteins will be devoid of these modiﬁca-
tions and the antibodies elicited may not recognize the
corresponding modiﬁed proteins expressed in the host.
2.3. Toll-Like receptor (TLR) and Nod-Like receptor (NLR) species-
speciﬁc recognition and escape of leptospires
Lipopolysaccharide (LPS) is composed of the lipid A, anchored
in the outer membrane, linked through the central core to the
polysaccharide O-antigen, which extends outside of the bacte-
rium. Lipid A, often referred to as endotoxin, is the agonist of the
TLR4 receptor. TLR4 activation leads to a strong inﬂammatory
response and to the recruitment and activation of phagocytes. The
favorable outcome of TLR4 activation is the clearance of the bac-
teria but if the inﬂammatory response becomes uncontrolled, the
host may die of septic shock, consecutive to a cytokine storm.
Leptospiral LPS is less endotoxic than LPS from the Gram-negative
bacteria such as Escherichia coli or Salmonella spp. L. interrogans'
lipid A escapes recognition by human TLR4, although murine TLR4
effectively detects it [14]. Consistent with this result, whilst WT
mice are largely asymptomatic, TLR4 deﬁcient mice are highly
sensitive to leptospirosis, and may die after intraperitoneal
infection with virulent L. interrogans. In human, murine, bovine
and pig cells, leptospiral LPS is also recognized by TLR2, which is
the lipoprotein receptor [22,31,32]. Since leptospiral lipid A is not
recognized by TLR2, the TLR2 recognition is most probably due to
a non-identiﬁed lipopeptide tightly attached to the core or O-
antigen part of the LPS. In mice, TLR4 and TLR2 activate B cells to
produce IgM and protective IgG directed against the LPS. TLR4 and
TLR2 are responsible for nitric oxide (NO) production, an efﬁcient
bactericidal effector that also exacerbates the renal disease. TLR2
and TLR4 also act together to induce IFN-g [15], which is impor-
tant to prime the phagocytic activity of macrophages. Of note, li-
poproteins are major components of the leptospiral cell wall;
more than 140 ORF encode putative lipoproteins, among them the
abundant LipL32, LigA, LigB, LipL21 and LoA22. These lipoproteins
are thought to be adhesins, binding cells or different components
of the extracellular matrix [33]. To date, only LipL32, which is the
major lipoprotein speciﬁc to pathogenic Leptospira spp., has been
shown to activate TLR2. The LipL32/TLR2 complex has been
studied in detail by crystallography, showing a Ca2þ -binding
cluster in LipL32, required for the interaction with TLR2 and
subsequent inﬂammatory signaling. A recent predictive structural
study using truncated Lip32 proteins suggests that the complex
formation depends on a hydrophobic interaction [34]. Interest-
ingly, one study highlighted that the LPS of L. interrogans serovar
Autumnalis strain 56606 only signals through murine TLR4, and
not through TLR2 [35]. The authors showed in a TLR4KO mouse
model that this strain induces a mild self-resolving acute lepto-
spirosis, affecting liver and lungs with no association to kidney
lesions [35]. Together, these results suggest that leptospires,
which are potent TLR2 agonists, could use the TLR2 response to
subvert and limit the host response. This is under investigation in
our laboratory. The recognition of leptospires by TLR involved in
nucleic acid recognition (such as TLR9) remains elusive. Ongoing
studies in our group also focus on the recognition or escape of
leptospires by TLR5 signaling.
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molysins [36] and Lsa21 [37]) are TLR2 and TLR4 agonists. It is highly
probable that these data are misleading since experiments were
performed with recombinant proteins produced in E. coli, a bacte-
rium expressing one of the most potent LPS. Although increasingly
common, using recombinant proteins to study inﬂammation and
innate responses in vitro constitutes a methodological ﬂaw. Indeed,
we showed that besides TLR4 activity, the LPS of E. coli is naturally
rich in contaminants that signals through TLR2, NOD1 and NOD2,
and that traces of endotoxin (less than 1 ng/ml) synergize with TLR
and NLR agonists to induce inﬂammatory responses [38]. Even if
contaminating endotoxins have been largely removed using LPS
binding polymixin-based resins, and the endotoxic activity of the
recombinant protein evaluated by the limulus amoebocyte lysate
(LAL) assay is low, synergies between traces amount of contami-
nating endotoxin and lipopeptides may occur [38] and account for
the observed TLR2/TLR4 activity [39]. To potentially overcome these
issues, we tried to express recombinant proteins in an lpxMmutant,
or engineered strains of E. coli, expressing penta-acylated lipid A,
which exhibited only weak TLR4 activity. However our datawere not
conclusive. The removal of contaminating lipopeptides was not
achieved and we found another overlooked issue. We observed that
the poly-histidine tag, commonly used to purify recombinant pro-
teins, interfered with the LAL assay. The dose responses were
inverted and showed that the more concentrated the protein, the
less endotoxin is detected (CW unpublished data about leptospiral
HSP70). Since recombinant proteins are often tested for endotoxin
contamination at very high concentrations used for cell stimulation
(0,5 mg/ml up to 50 mg/ml), the measure of the endotoxin content
may be largely underestimated.
The same bias may be highlighted in a study describing
LIC11207 [40], potentially involved in delaying neutrophil
apoptosis. This study used a recombinant protein, inevitably
contaminated with endotoxin, which is well known to exert an
anti-apoptotic effect through NF-kВ activation. Such issues there-
fore put the results into question, even though the authors used
polymyxin and LPS as controls. In this study and in others, the use
of an unrelated protein as a negative control for the phenotype
observed can also be misleading, because endotoxin contamination
will not be the same depending on the hydrophobicity/polarity of
the protein.Fig. 1. LipL21 blocks peptidoglycan recognitionTherefore, to avoid these pitfalls, one should absolutely refrain
from using those recombinant proteins produced in bacteria to
investigate innate immunity. An alternative is to produce lepto-
spiral recombinant proteins in eukaryotic hosts such as Drosophila
cells, but not in yeast as the same problem of MAMPs contamina-
tion may occur. Nevertheless, recombinant proteins produced in
bacteria or yeast have proven very useful in different contexts such
as adhesion assays or vaccines. For the latter, the LPS/lipopeptide
contamination may provide an interesting adjuvant effect to a
given antigen.
IL-1b is a central cytokine in inﬂammation, important for the
expression of other pro-inﬂammatory cytokines, and whose
secretion is tightly controlled by the “inﬂammasome” [22]. We
showed in mice that leptospiral LPS and lipoproteins prime
NLRP3 inﬂammasome and pro-IL-1b mRNA expression. Addi-
tionally, the inhibition of the sodium/potassium (Na/K) pump by
glycolipoprotein, an outer membrane component, results in
NLRP3 activation and processing of the pro-IL-1b protein to
secreted IL-1b [41]. A recent study highlighted a novel role for
doxycyclin in inhibiting the IL-1b production in mouse and
hamsters cells infected with leptospires [42]. One speciﬁc effect
of doxycyclin is to restore the Na/K pump expression that is
inhibited by leptospires, while another role (not speciﬁc to lep-
tospires) is to downregulate NLRP3 and IL-1b mRNAs. Altogether,
this results in blunting the inﬂammasome priming and activation
and consequently blocks the IL-1b secretion and associated
inﬂammation.
Our recent work showed that L. interrogans escape recognition
by the cytosolic innate NOD1 and NOD2 receptors, which recognize
peptidoglycan fragments called muropeptides [43]. Indeed, we
showed that these receptors are not important for the clearance of
L. interrogans in mice. This was unexpected since all invasive bac-
teria, either extracellular or intracellular, are sensed by the NOD
receptors. We found that the LipL21 lipoprotein binds to the
peptidoglycan and impairs its degradation into muropeptides,
which therefore cannot signal through NOD1 and NOD2 (Fig. 1).
This protective role of LipL21 seems to be unique to Leptospira spp.,
since comparison of sequences did not show homology of LipL21
with any other bacterial protein [43]. In addition, we also found a
peculiarity of the leptospiral PG composition that inﬂuences the
species recognition by the NOD1 receptor. Once digested bythrough the NOD1 and NOD2 receptors.
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major muropeptide component of the E. coli's PG, which is the
preferential agonist of the murine (m)NOD1. In contrast, we found
that leptospiral PG is well recognized by the human (h)NOD1 since
the major muropeptide is the GM-triDAP, the preferential hNOD1
agonist. Therefore, these results suggest that leptospires counteract
both NOD1 and NOD2 receptors. In mice, the presence of LipL21
would only be useful to avoid the NOD2 response since the mNOD1
does not recognize the leptospiral PG. In humans, LipL21 would be
more important since the leptospiral PG is perfectly recognized by
both NOD1 and NOD2. Our group is now studying the functional
consequences of the escape of NOD1 and NOD2 recognition by
leptospires in terms of phagocyte functions.
Altogether, the species speciﬁcity of TLR4 and NOD1 suggest
that a careful study of the recognition of leptospiral cell wall
components (LPS, lipoproteins, ﬂagellins, muropeptides …) by the
TLR and NLR of different animals would be instrumental to deter-
mine their susceptibility to leptospirosis. These studies may bring
interesting insight into the outcome of leptospirosis in different
animals, and help to design tailored vaccines, according to the
species to be protected.
2.4. How L. interrogans establish renal chronicity?
We showed by live imaging using a bioluminescent
L. interrogans strain, that following intraperitoneal infection of mice
with more than 106 bacteria, leptospires replicate in blood, and 1
week post infection disappear from the circulation. They then
reappear in the kidneys, where they progressively expand until a
stable colonization is established, which occurs 15 days to 1-month
post infection [1]. Hamsters have also been shown to be chronic
carriers of leptospires when surviving experimental infection
[44,2]. Recently, the Yoshida group used a hamster model of in-
tradermal inoculation to track post-mortem, after laparotomy, the
Murray's LuxCDABE-luminescent L. interrogans. Of great interest,
they showed that leptospires ﬁrst disseminate in the subcutaneous
adipose tissue before disseminating in the blood and colonizing the
organs including the kidneys [45]. Eye drop inoculation is an
interesting route of infection since it mimics a natural route of
infection and is considered more physiological than intraperitoneal
infection, which bypasses the natural defenses of the skin and
mucosa. Recently, the Gomes-Solecki group showed in the C3H/HeJ
TLR4 deﬁcient mouse model that eye inoculation with 108
L. interrogans leads to acute leptospirosis with kidney lesions and
colonization, although with a delay compared to the intraperito-
neal route [46].
An interesting ﬁnding recently emerged about the potential
role of IL-10, an anti-inﬂammatory cytokine, in renal colonization.
Comparison of cytokines proﬁles in hamsters and mice infected
with leptospires, showed that hamsters, which are sensitive to
leptospirosis, express more IL-10 than resistant mice. This
augmentation occurs both during the acute phase in the blood and
also in kidneys one month post infection [2,47]. Interestingly,
another study showed that infected IL-10KO mice, in contrast to
WT mice, do not exhibit renal colonization. As already stated (in
2.3), IFN-g is a crucial cytokine, decisive for the microbicidal ac-
tivity of macrophages. IL-10KO mice expressed more IFN-g in the
kidneys than WT mice [48]. Up-regulation of IL-10 by leptospires
would dampen the IFN-g expression, which would limit the
bacterial clearance, hence favoring a chronic infection. Interest-
ingly, it has recently been shown that the IL-10 secretion in the
kidneys relies on the TLR2 pathway triggered by leptospires [49].
These data should encourage novel strategies aimed at enhancing
phagocytic activity to avoid or limit leptospiral colonization in
kidneys.2.5. How leptospires maintain chronic infection?
We strikingly showed a sustained, lifetime asymptomatic renal
colonization of L. interrogans in mice after intraperitoneal infection
[1]. Our results suggest that leptospires are conﬁned in their spe-
ciﬁc proximal tubule niche and do not expand into new tubules.
This could be explained by circulating neutralizing antibodies that
could block the exit of leptospires from the tubules and would not
allow the expansion of leptospires in the kidney. The proximal tu-
bule is therefore an “immune privileged” site for pathogenic Lep-
tospira spp., but the reason for such an association is unknown. An
easy speculation would be that the proximal tubule provides a
favorable nutritive environment to leptospires. However, the
epithelial layer of the proximal tubule in contact with leptospires is
known to express numerous TLR and NLR receptors that will pro-
duce antimicrobial peptides upon activation [50]. How leptospires
succeed at overcoming this immune defense is a puzzling question.
Several ideas are emerging in our ﬁeld.
Once in their renal niche, we showed in mice that L. interrogans
were not eradicated by antibiotic treatments, although the same
treatments were efﬁcient during the acute phase of infection when
leptospires are in the blood. This is in accordance with clinical data
showing that antibiotic treatments are effective only if adminis-
tered early. Once the antibiotic treatment of mice is over, lepto-
spires repopulate their niche, although to a lesser level [1]. We
checked that the bacteria were not resistant to the antibiotic, sug-
gesting that these bacteria in tubules are persistent bacteria. As
shown in the rat model, these data combined with microscopic
studies suggest that leptospires establish dense colonization in the
mouse proximal tubules, reminiscent of bioﬁlms. Persisters are
dormant bacteria with low metabolism and are supposed to be
responsible for bioﬁlm antibiotic resistance. Strategies combining
classical antibiotics with drugs able to disperse bioﬁlms should be
tested. The use of bioluminescent leptospires tomonitor the kidney
infection could ease these trials.
Recent studies have highlighted the peculiar role of toxin-
antitoxins systems [51] and transporters that pump antibiotics
out of persister cells [52]. Different toxin/antitoxin modules are
present in the genome of leptospires [53e56], and the toxins ChpK
and MazF have been shown to be expressed and toxic upon
leptospiral infection of human THP-1 macrophages [53]. Future
studies of the potential role in virulence and dormancy of these
genes upon chronic leptospirosis may be of interest.
2.6. Inﬂuence of sex during the course of infection
It is established that several criteria inﬂuence the degree of
severity of leptospirosis; they include the serologic antecedent of a
ﬁrst infection, the infectious dose, the serogroup/serovar of the
infecting strain and genetic determinants of the host [57]. In
addition, the predisposition related to the sex of individuals is
questioned. Indeed, several studies show that leptospirosis more
often affects men, with a possible bias consecutive to the practice of
activities associated with an increased risk of leptospiral infection
[58]. Although prevalence of anti-Leptospira antibodies in both
genders was shown to be equivalent regardless of the geographic
region inﬂuence [59,60], thereby suggesting an equal incidence of
infection, thorough epidemiological studies show that males are
more often hospitalized and more susceptible to development of
severe disease than women [61,62]. Interestingly, an increased
male susceptibility was recently reported in a sub-lethal infection
model in hamsters, in which males were more prone to develop
pulmonary haemorrhage than females [63]. In the latter, an up-
regulation of nitric oxide (NO) synthase genes in the lungs was
associated with the lack of leptospiral detection, and therefore was
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monary damages due to leptospirosis. This is in linewith our results
showing an upregulation of iNOS in lungs and kidneys of wild-type
asymptomatic C56BL/6 mice, whereas mice deﬁcient for both TLR2
and TLR4, highly sensitive to acute leptospirosis, did not up-
regulate iNOS [15]. Interestingly, a gender difference has been re-
ported regarding the immune responses in mouse airways after LPS
sensitization. Males were found to have increased response of pro-
inﬂammatory cytokines [64]. However the authors did not ﬁnd any
difference in expression of TLR4 in males and females, suggesting
that TLR4 did not underlie this gender difference [64]. To our
knowledge, a gender bias of susceptibility to acute leptospirosis in
mice has never been reported, but most published experiments
were performed using females [16]. In our hands, using C56BL/6
mice, we tested both sexes and did not observe a bias in the sus-
ceptibility to acute leptospirosis, in terms of lethality, bacterial
loads and cytokines production in the liver and the kidneys during
the acute phase of infection. Also, using live imaging to check renal
colonization, we did not see any difference in the intensity of renal
colonization between males and females (unpublished data).
Similar results have been reported from the observation of renal
colonization in rats from urban slums in Brazil [65]. Therefore, to be
truly informative about the inﬂuence of sex in the severity of
leptospirosis, analyses should include different animal models,
target organs, a panel of strains of different serogroups/serovars,
and be performed over a longer period of time to test not only the
acute phase but also the long term consequences of chronic infec-
tion. Considering that pulmonary haemorrhaging has emerged as
an important clinical syndrome of human leptospirosis, associated
with the highest burden on lethality [66,61], studies to understand
the hormonal or genetic component inﬂuencing the increased
resistance of females could be an important step toward future
strategies to limit severe leptospirosis.
3. New approaches to design drugs and vaccines
3.1. Antimicrobial drugs
Whole blood transcriptomic analyses in leptospirosis patients
have recently identiﬁed elevated transcripts of effectors involved in
the pro-inﬂammatory signaling pathways and low expression of
both the RANTES cytokine and the antimicrobial peptide cath-
elicidin (LL37) as a correlate to a poor clinical outcome of severe or
fatal leptospirosis [67]. Moreover, treatment with synthetic LL37 at
the time of infection reduced the bacterial load in blood and
rescued 40% of hamsters from a lethal challenge with L. interrogans
[67]. This study is important since it may open a new avenue to
treat human leptospirosis. The recent ﬁnding that LL37 activates
NET formation and reduces inﬂammation [68] may provide a po-
tential mechanism for the observed protection of hamsters at the
acute phase of infection, when both the bacterial load and
inﬂammation are reaching their peak. BMAP, a bovine equivalent of
LL37, has been shown to bind LPS and to decrease, in vitro, the
leptospiral LPS induced signaling [31], which is important to elicit
inﬂammation. Studies still need to determine whether LL37 can be
used as a prophylactic treatment and/or, if it is active when
administered after experimental infection. However, potentially
precluding therapeutic trials, LL37 has recently been shown to be a
T-cell auto antigen in psoriasis [69].
Taking advantage of the known anti-bacterial activity of pyrans
and heterocycles, pyranoisoxazolones were recently synthesized
and shown to constitute novel, safe and speciﬁc drugs against
Leptospira spp. Interestingly, some derivatives, tested in vitro, were
shown to bemore efﬁcient than doxycyclin, the reference antibiotic
treatment, and active against pathogenic but not saprophyticLeptospira spp. The most active compound could rescue cyclo-
phosphamide sensitized Balb/c mice from a lethal challenge with
L. interrogans serovar Canicola. Of note, this compound also proved
efﬁcient to avoid renal colonization. Interestingly, in silico docking
experiments suggested that this compound could bind to LipL32,
expressed only in pathogenic strains [70], potentially explaining
the lack of effect on saprophytic strains. However, further investi-
gation is required to understand if binding to LipL32 can explain the
toxicity of these drugs towards pathogenic leptospires. If true, this
observation may add one more level of complexity regarding the
mysterious role of LipL32 which is not required for growth in vitro,
and is perfectly conserved in all pathogenic strains, but dispensable
for acute or chronic infection [71].
A novel approach to discover efﬁcient antibacterial agents is
based on chemogenomics, and consists at using genetics, structure
prediction, virtual screening and 3D structure docking to ﬁnd drugs
and derivatives in ligand libraries targeting several proteins of the
same family. A ﬁrst study deciphered, by substractive genomics, the
different families of proteins, conserved between pathogenic
strains of leptospires [72]. One of these families corresponds to the
Mur ligases, involved in the peptidoglycan biosynthetic pathway.
This pathway is essential for prokaryotes but absent in eukaryotes
and is therefore a good target for antibacterial drugs. The MurD
ligasewas further screened against a preexisting ligand library [73].
Using the information obtained in the MurD screen as a lead to
model the 3D-structure and activity of ligands and target proteins,
the authors found novel ligands of MurC and MurF [74]. Those
drugs still await in vitro and in vivo testing to prove their efﬁciency
against leptospires.
3.2. Reverse and structural vaccinology (RV)
RV is a computational biostatistical approach to mine bacterial
genomes to search for conserved and protective antigens that could
be good vaccine candidates, i.e. genes of secreted or surface
exposed proteins or lipoproteins, and predicted to bear B and T
epitopes. This technique has recently been implemented for lep-
tospires (for comprehensive recent reviews see Refs. [75] and [76]).
In 2006, the Yang group obtained the ﬁrst results using bioinfor-
matics and analysis based on the theory of reverse vaccinology.
They identiﬁed, in the genome of L. interrogans serovar Lai strain
56601, 226 genes encoding potentially surface-exposed proteins
that might be useful as vaccine candidates [77]. Also, the Haake's
group in 2009 used b-barrel prediction programs to identify 4 novel
outer membrane proteins of L. interrogans serovar Copenhageni
strain Fiocruz L1-130 [78].
Two RV studies that identiﬁed conserved vaccine candidates of
L. interrogans were recently published [75,79]. In the ﬁrst, the
genome of L. interrogans serovar Copenhageni was mined for
predicted outer membrane proteins and lipoproteins. Among
these proteins, the conserved orthologs present in all the patho-
genic serovars, harboring outer membrane b barrel domains, were
further modeled in 3D. Peptides predicted to be surface exposed
epitopes of major histocompatibility complex of class II molecules
were mapped on the proteins, giving information about their
potential immunogenicity [80,76]. This study identiﬁed 18 outer
membrane proteins, including 8 outer membrane lipoproteins,
TolC efﬂux pumps and several TonB-dependent transporters, that
bind and transport siderophores, metals, and vitamins [80]. In the
second study, the genome of L. interrogans serovar Lai strain 56601
was screened with a negative RV approach to exclude the inner
membrane and cytosolic proteins, which are usually reliably
predicted, in order not to miss potential secreted or outer mem-
brane antigens, which are not always properly annotated. One
hundred and twenty-one conserved orthologs from 17
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ﬁed [79]. Among these potential vaccine candidates against
leptospirosis, several are known to be antigenic in human pa-
tients, and some orthologs have been shown to be protective
against other bacterial infections. Interestingly, 9 outer membrane
proteins, including TonB-dependent transporters, constitute
promising candidates since they were found in both studies. All
these leptospiral vaccine candidates await in vivo testing. A careful
analysis of these different RV studies should help to reﬁne and
reduce the number of conserved vaccine candidates to test on
animals.
The ﬁrst large scale reverse genetic screen to identify vaccine
candidates, that were further tested in vivo, was performed by
Murray and Adler, who found 262 genes corresponding to pre-
dicted outer membrane proteins or lipoproteins in the genome of
L. borgpeterseni serovar Hardjo [44]. Two hundred and thirty eight
genes were cloned in E. coli and recombinant proteins were puri-
ﬁed. Pools of 5 recombinant proteins were mixed with alum as
adjuvant and injected twice in hamsters. Six weeks after the ﬁrst
immunization, the hamsters were challenged with a strain of
L. borgpeterseni serovar Hardjo that is not lethal but colonizes the
kidney. Although most of these proteins elicited speciﬁc antibodies
and were therefore immunogenic, they did not protect the ham-
sters from renal colonization [44]. This tremendous work consti-
tutes a reference for further studies, as it provides a consequent list
of recombinant proteins that proved to be inefﬁcient as vaccine
candidates. It is also a suggestive example of how difﬁcult it may be
to generate successful vaccines against leptospires using recombi-
nant whole proteins expressed in E. coli, as leptospires are known to
modify their proteins in vivowith post-translational modiﬁcations,
not performed in E. coli (see 2.2).Fig. 2. Comparison of immunization protocols with LigB vaccines giving different outcomes G
in red correspond to the differences that we hypothesized to be the most important.3.3. Subunit vaccines
The leptospiral immunoglobulin-like (Lig)A and LigB are outer
membrane lipoproteins that have been extensively studied as
vaccine candidates since they are major antigens in patients with
leptospirosis (reviewed in Ref. [7]). They are long modular proteins
with 12 repeats of immunoglobulin-like domains, extending from
the outer membrane. LigA and LigB are similar in their N-terminal
parts but only LigB is conserved among the L. interrogans strains.
These proteins are involved in adhesion to extracellular matrix
components and have recently been shown to bind host factors that
could be important to avoid complement killing during infection.
Haake's [81] and McBride's [13] groups recently published about
the use of part of these modular proteins as subunit vaccines, in the
hamster model of leptospirosis. In Haake's study, although both the
recombinant proteins expressing the surface exposed part of LigA
(carboxy-terminal part), or the N-terminal part of LigB, were
immunogenic, only the construct with LigAwas protective against a
lethal challenge with L. interrogans copenhageni strain Fiocruz L1-
130 in the hamster model [81]. However, the LigA vaccine failed
to achieve kidney sterilization [81]. Surprisingly, in McBride's
study, almost the same LigB recombinant protein (N-terminal re-
gion of LigB, without the signal peptide) successfully rescued the
hamsters from the lethal challenge and sterilized the kidneys [13].
The protection was not dependent of the dose since same protec-
tion was achieved with 100 mg and 20 mg of vaccine.
Careful comparison of the differences between the immuniza-
tion protocols of these two studies, using almost the same LigB
antigen, same dose and same leptospiral strain for challenge, but
giving different outcomes, could give some hints towards obtaining
efﬁcient subunit vaccines (Fig. 2). Among the following differences,reen represents the successful vaccine, pink the one that did not protect. D: day. Words
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versus (vs) failure [13,81]: production of the recombinant LigB
protein (denatured/renatured vs soluble); adjuvants (aluminium
hydroxide vs complete/incomplete Freund adjuvant (CFA/IFA));
number of injections and immunization route (2 intramuscular vs 3
subcutaneous); number of leptospires to challenge and kill 100% of
non vaccinated hamsters (200 vs 10,000, representing 10e500 fold
the Lethal Dose 50) ? The answer to this question (discussed in
Ref. [81]) is of crucial importance to lead future successful trials. In
our opinion even though both studies showed 100% death of ani-
mals, Haake's challenge with 10,000 bacteria was more drastic than
the 200 bacteria used by theMcBride group. The immune system of
the hamsters was hence less challenged in McBride's study,
potentially explaining a better outcome of this vaccine. Ideally, the
repeat of each immunization route and challenge conditions using
the other group's construct could be a very potent way to under-
stand the key factors for successful immunization with recombi-
nant proteins.
The Yan group recently published a very interesting study about
a multi-epitope chimeric recombinant leptospiral vaccine. This
vaccine consists in 4 repeats of a fragment combining 2 previously
identiﬁed immunodominant B and T cell epitopes of each of the 3
major outer membrane proteins OmpL1, LipL32 and LipL21
(conserved and expressed in pathogenic strains) [82]. This vaccine,
adjuvanted with alum, and administered subcutaneously, was used
in the guinea-pig model of lethal infectionwith L. interrogans strain
Lai. It was protective and rescued 80% of the challenged guinea pigs
from death. The vaccine markedly decreased the renal lesions and
leptospiral renal colonizationwas not apparent, as shown by lack of
silver staining of leptospires in renal tubules, negative cultures of
kidneys and lack of visible leptospires in urine. Interestingly, lym-
phocytes of guinea pigs stimulated ex vivowith the vaccine showed
a Th1 polarized response with IFN-g production. Therefore, this
approach is very promising since T cells are recruited in the kidney
after leptospiral infection, whilst IFN-g has an important protective
role to avoid renal colonization of leptospires (see part 2.4). How-
ever, both the potential renal sterilization and the expected pro-
tection against different serovars remain to be demonstrated.
3.4. Adjuvants
Besides differences in the number and routes of injections in the
LigB studies [13,81], one of the major difference was the adjuvant
used. Indeed, once good antigen candidates are obtained, the
choice of adjuvant is critical.
The Haake group used CFA whereas the McBride group used
alum,which is licensed for human vaccines. Alum is one of themost
potent adjuvants; it induces a Th2 response by improving the
attraction and uptake of antigen by antigen-presenting cells. It
activates the NLRP3 inﬂammasome to produce IL1-b, leading to
neutrophil recruitment at the site of injection and T cells activation
[83]. On the other hand, CFA is an emulsion of cell wall components
of inactivated driedmycobacteria in mineral oil, usually mixed with
a soluble antigen. It has been shown to stimulate NOD2 through
MDP. It is however not licensed for humans because of its toxicity,
provoking granulomatous inﬂammatory lesions, and its use in an-
imal experimentation is no longer recommended.
Other PRR agonists may also be good adjuvants. In the ham-
ster, a co-injection of L. interrogans serovar Automnalis with the
synthetic TLR2 agonist Pam3cysSK4 alleviated the pathology,
reduced the bacterial load in organs and improved survival [49].
Interestingly, the authors show that this beneﬁcial effect is
correlated with an early up-regulation of TLR2 in mice compared
to a delayed TLR2 expression in hamsters. However how these
results can be reconciled with the IL-10 production induced byleptospires (described above) to dampen the IFN-g (see para-
graph 2.4) is unclear. In this case, TLR2 activation has a positive
outcome for the host, whereas it was positive for the bacteria
when inducing IL-10.
A recent study compared the protection conferred by two
different adjuvants added to a multivalent vaccine in the hamster
model of leptospirosis. Pools of selected recombinant conserved
outer membrane of leptospiral proteins, complemented or not with
a recombinant LigA part (C-term portion), were mixed either with
alum or Salmonella Flagellin (FliC) [84]. FliC is a potent agonist of
the TLR5 receptor and is a successful vaccine adjuvant. Interest-
ingly, whilst both vaccines with recombinant LigA rescued the
hamster after a lethal challenge, only the FliC adjuvant signiﬁcantly
decreased renal colonization, although leptospires were still pre-
sent in the kidney. This approach is promising since renal sterili-
zation is the hurdle of most leptospiral vaccine trials. Ongoing
studies in our group are studying leptospiral recognition/escape by
TLR5. Preliminary results suggest that pathogenic Leptospira spp.
may naturally escape this defense due to the peculiar localization of
the endoﬂagellum. Strategies aimed at restoring the TLR5 defense
are therefore also very promising.
3.5. Oral vaccines
Oral vaccination presents several practical advantages over
parenteral immunization in developing countries and specialized
practitioners are not required to administer the injection. Addi-
tionally, oral immunization could be very interesting against a
zoonosis like leptospirosis since the vaccines can be widely
distributed in food pellets. Mucosal immunization may provide a
more appropriate immune response than other routes since
pathogenic Leptospira spp. use the mucosal route to infect their
hosts. The Gomes-Solecki group recently used live bacteria [85,86]
to orally deliver leptospiral antigens. In the ﬁrst study, live E. coli
expressing the C-term part of LigA, were administered daily to
hamsters by oral gavage for a period of 4 non-consecutive weeks,
before lethal challenge with the strain Fiocruz L1-130 of
L. interrogans serovar Copenhageni. The LigA construct was
modiﬁed with the inclusion of a signal peptide of the OspA lipo-
protein from Borrelia spp., conferring a lipidated anchor and a
proper localization of the LigA protein at the outer surface of
E. coli. This recombinant E. coli strain expressing LigA induced a
high and speciﬁc antibody response and rescued 40e60% of the
hamsters from death. However, it did not prevent renal coloni-
zation in survivors [85]. Nevertheless, this study demonstrated
the feasibility of using a whole organism as a carrier of leptospiral
proteins expressed at its surface to induce an immune response
against leptospires after oral administration. The yeast Saccharo-
myces boulardi, administered in food pellets, and generally
recognized as a safe (GRAS) organism, was recently shown to
enhance the antibody and cytokine responses in Balb/C mice after
3 injections of DNA vaccines expressing LigA or LigB fragments
[87]. However, no challenge was done with L. interrogans and it is
not known whether S. boulardi improves protection against live
bacteria.
Another study used the probiotic Lactobacillus plantarum, a
GRAS organism known for its immunomodulatory properties. As a
ﬁrst step towards the use of L. plantarum as an oral vaccine
expressing leptospiral epitopes, C3H/HeJ mice were orally gavaged
for several weeks with the non-recombinant L. plantarum, before
intraperitoneal infection with Fiocruz strain L1-130. Interestingly,
Lactobacillus treatment alleviated acute leptospirosis and reduced
the renal lesions, although it did not prevent renal colonization. The
beneﬁcial effect on the kidneys was correlated with less inﬂam-
mation and higher recruitment of myeloid cells, in particular
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ising and ongoing studies are testing different leptospiral proteins
expressed in L. plantarum (Gomes-Solecki, personal
communication).
4. Conclusions
A universal leptospirosis vaccine, safe in humans and protective
against all pathogenic Leptospira spp., remains a long-range goal,
out of immediate reach. Because of the difﬁculties of accurate
diagnosis and risks of chronic infection, different preventatives,
such as efﬁcient drugs or vaccines, should be developed in parallel.
To mimic the natural infection, these preventatives should be
tested using recently developed animal models challenged through
physiological routes.
This last decade, very interesting techniques such as reverse/
structural vaccinology and CRISPR/CAS 9 technologies have opened
great prospects and should rapidly ease the research in the ﬁeld of
leptospiral vaccines. Moreover, accurate and sensitive qPCR, and
the availability of virulent bioluminescent strains to track the
presence of leptospires after challenge, should facilitate vaccine
screening. Rats and mice are not always the reservoirs involved in
human contamination, and local animals have recently being
shown to be overlooked reservoirs favoring human leptospirosis.
Hence, local campaigns of mass urine sampling of humans and
animals should be organized for both epidemiologic and diagnostic
purposes. The identiﬁcation of asymptomatic humans and animals
and circulating serovars would provide the rational for the selec-
tion of appropriate strains to use as vaccines. This would also be
very important to properly target the relevant animal populations
to vaccinate.
Nevertheless, several factors constitute a hurdle against devel-
opment of effective leptospirosis vaccines.
1 Very basic knowledge regarding the antibody kinetics and the
duration of protection after experimental infection is not
available for most animal models of leptospirosis. It is therefore
difﬁcult to determine whether vaccines could confer long-term
protection. The research of vaccines against Leptospira spp. also
suffers from the lack of correlates of protection (for a compre-
hensive discussion see Ref. [44]). Indeed, in the case of lepto-
spirosis, the serological response induced by a vaccine is usually
not correlated with efﬁcient protection. The increasing trend to
limit animal use because of ethical concerns should be seriously
taken into account. One can imagine that correlates of protec-
tion could be, in the near future, a pre-requisite to obtain ethical
authorization to challenge animals after immunization. There-
fore, our ﬁeld should focus on developing other strategies to test
vaccine effects, for example, the measurement of dendritic cells
responses after in vitro stimulation with the vaccine or bacte-
ricidal phagocytic assays with sera obtained after animal
immunization.
2 In vivo, modulation of LPS or proteins by post-translation
modiﬁcations are most probably responsible for the lack of
recognition by antibodies elicited after immunization with
strains grown in vitro (e.g in EMJH). Ideally, retrieving lepto-
spires from blood during the hematogenous dissemination
would be the best option to obtain proteins with their ﬁnal
conformation (with PTM) as a source of antigens. However this
is hardly feasible. The new technique to grow leptospires in vivo
(such as the DMC device) could be a nice alternative in some
large animals. Another amenable source of host-adapted
leptospire strains is the urine. Proteomic studies could be per-
formed using leptospires retrieved from animal and human
urine to ﬁnd antigens that are not the target of PTM.3 The lipidation of spirochetal proteins confers a potent TLR2 ac-
tivity, due to the triacylated anchor. The borrelial lipoprotein
OspA, already successfully used in vaccines, LipL32 and most
probably other leptospiral lipoproteins, are TLR2 agonists. TLR2
agonists have been shown to stimulate dendritic cells and
confer subsequent protection against bacterial infections [88]. In
the case of leptospirosis, a TLR2 agonist has been shown to be an
interesting adjuvant (see 3.4), and lipidated LigA, used in the
ﬁrst oral vaccine, provided a good humoral response (see 3.5).
Therefore, the incorporation of a lipid moiety in peptide-based
vaccines should be a good strategy for leptospiral vaccines.
4 Other factors are overlooked, such as the reasonwhy there is no
immune memory, after leptospiral infection or immunization
with bacterins. One simple explanation could be that the LPS
masks the responses to conserved proteins. However in the
serum of patients, antibodies against several conserved proteins
such as LipL32 are found. If TLR2 agonists are good adjuvant and
promote T cell responses, why don't leptospires, which are very
potent TLR2 agonists, trigger immune memory? This is one
question currently being addressed by our group.
5 The lack of targeted mutagenesis has hampered the leptospiral
ﬁeld, however, it is now possible to express heterologous pro-
teins in pathogenic strains from a replicating plasmid (pMAORI),
which constitutes a major advance [89]. The new era of genome
manipulation with the CRISPR/CAS9 system should encourage
trials to construct safe live-attenuated strains complemented in
essential genes for in vitro culture, as has been done for Sal-
monella spp. Also, the new pMAORI plasmid allows the
expression of heterogeneous proteins in pathogenic species,
which could be used to “adjuvant” the leptospires.
In conclusion, to counteract leptospirosis, which is still not yet
recognized by the WHO as a neglected disease, we need to
combine several approaches to construct and optimize novel
vaccines. The starting point could be existing vaccines, such as the
live attenuated LPS mutant and recombinant LigB vaccines. It
could be useful to adjuvant these vaccines with TLR/NLR agonists
to try to improve their efﬁciency. A rational exploration of the
recognition (or escape) of Leptospira spp. by receptors and com-
ponents of the immune system is essential. The escape from TLR
and NLR receptors should give some information of how to boost
the immune system to alleviate the infection and potentially avoid
renal colonization. The escape from complement should also give
clues to obtain vaccines that are sensitive to complement and
properly processed by phagocytes, potentially eliciting effective B
and T cell memory.
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